by The antidiabetics market size is poised to grow by USD 227.50 billion by 2033 from USD 98.20 billion in 2023, exhibiting a CAGR of 8.76% during the forecast period 2024-2033.
Key Points
- North America has held the largest revenue share of around 39% in 2023.
- Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
- By product, the insulin segment dominated the antidiabetics market with the highest share in 2023.
- By product, the drug class segment is observed to grow at a significant rate during the forecast period.
- By patient population, the geriatric segment held the dominating share of the market in 2023.
- By route of administration, the oral segment led the market in 2023. The segment is observed to sustain the position.
- By route of administration, the insulin pen/syringe segment is observed to witness the fastest rate of expansion throughout the forecast period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Antidiabetics market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Antidiabetics Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3914
Antidiabetics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 8.76% |
| Global Market Size in 2023 | USD 98.20 Billion |
| Global Market Size by 2033 | USD 227.50 Billion |
| U.S. Market Size in 2023 | USD 30.26 Billion |
| U.S. Market Size by 2033 | USD 70.09 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Patient Population, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: AI in Computer Vision Market Size to Rise USD 274.80 Bn by 2033
The empirical study on the global Antidiabetics market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Antidiabetics Market. Our market report for the Antidiabetics market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Antidiabetic Market Companies
- Sanofi-Aventis
- Takeda Pharmaceuticals
- Eli Lilly
- Oramed Pharmaceuticals
- Boehringer Ingelheim
- Merck & Co. Inc.
- Novo Nordisk
- Bristol-Myers Squibb
- Halozyme Therapeutics
- Pfizer
Data Sources and Methodology
To gather comprehensive insights on the Global Antidiabetics Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Antidiabetics Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Antidiabetics market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2024 to 2033.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Product
- Insulin
- Rapid Acting
- Long Acting
- Premixed Insulin
- Short Acting
- Drug Class
- Biguanides
- GLP-Agonists
- Thiazolidinediones
- Sulphonylureas
- SGLT-2
- Alpha-Glucosidase Inhibitors
- DPP-4 Inhibitors
- Meglitinides
By Patient Population
- Pediatric
- Adults
- Geriatric
By Route of Administration
- Oral
- Infusion
- Intravenous
- Insulin Pump
- Insulin Pen/Syringe
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Antidiabetics market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Antidiabetics market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Antidiabetics market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Antidiabetics market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antidiabetics Market
5.1. COVID-19 Landscape: Antidiabetics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antidiabetics Market, By Product
8.1. Antidiabetics Market Revenue and Volume, by Product, 2024-2033
8.1.1 Insulin
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Drug Class
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Antidiabetics Market, By Patient Population
9.1. Antidiabetics Market Revenue and Volume, by Patient Population, 2024-2033
9.1.1. Pediatric
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Adults
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Geriatric
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Antidiabetics Market, By Route of Administration
10.1. Antidiabetics Market Revenue and Volume, by Route of Administration, 2024-2033
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Infusion
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Intravenous
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. Insulin Pump
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
10.1.5. Insulin Pen/Syringe
10.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Antidiabetics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
Chapter 12. Company Profiles
12.1. Sanofi-Aventis
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Takeda Pharmaceuticals
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Oramed Pharmaceuticals
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Boehringer Ingelheim
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck & Co. Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novo Nordisk
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Halozyme Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
